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The glial environment is an important determinant of neuronal health in experimental models of neurodegeneration. Speciﬁcally,
astrocytes have been shown, dependent on context, to be both injurious and protective. Human pluripotent stem cells offer a
powerful new system to improve our understanding of the mechanisms underlying astrocyte-mediated neuroprotection. Here,
we describe a human embryonic stem cell (HESC)-based system to assess the scope and mechanism of human astrocyte-
mediated neuroprotection. We ﬁrst report the generation of enriched and functional HESC-derived astrocytes, by combining
BMP-mediatedSmadand LIF-mediated JAK-STATsignalling.These astrocytespromote the protectionofHESC-derived neurons
against oxidative insults. Moreover, their neuroprotective capacity can be greatly enhancedby treatment with the nuclear factor-
erythroid 2-related factor 2 (Nrf2)-activating triterpenoid 1[2-Cyano-3,12-dioxool-eana-1,9(11)-dien-28-oyl] triﬂuoroethylamide
(CDDO
TFEA). Activation of the transcription factor Nrf2 in human astrocytes by CDDO
TFEA treatment induced expression of the
glutamate-cysteine ligase (GCL) catalytic subunit, leading to enhanced GCL activity and glutathione production, and strong
neuroprotection against H2O2. This enhanced neuroprotection was found to be dependent on astrocytic GCL activity, unlike the
basal neuroprotection afforded by untreated astrocytes. Direct treatment of HESC-derived neurons with CDDO
TFEA elicited no
induction of Nrf2 target genes, nor any neuroprotection. Thus, human astrocytes can mediate neuroprotection through
glutathione-dependent and glutathione-independent mechanisms, and represent a therapeutic target for human disorders
associated with neuronal oxidative stress.
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Neurodegenerative diseases such as Alzheimer’s disease,
Parkinson’s disease, and amyotrophic lateral sclerosis (ALS)
are untreatable conditions that collectively represent a major
healthcare burden. Improved understanding of the biology of
these diseases is required in order to develop neuroprotective
and ultimately reparative treatments. Until recently, neurode-
generative diseases have been largely regarded as exclu-
sively neuronal disorders. However, recent ﬁndings have
challenged this concept, implicating non-cell-autonomous
mechanisms of neurodegeneration mediated by astrocytes
in acute and chronic disorders.
1,2
The role of astrocytes in inﬂuencing neuronal viability has
primarily been characterised in rodent systems. Advances in
human stem cell biology now allow the modelling of human
astrocyte–neuronal interaction under physiological and injury
paradigms. Although there are robust platforms for the
generation of neural stem cells and functional neurons, the
generation of enriched and functional human astrocytes is
comparatively understudied.
3,4 While our understanding of
astrogliogenesis remains incomplete, it is well established
that neurogenesis precedes gliogenesis and this in turn is
reﬂected in differential temporal phenotypic potential of neural
precursor cells (NPCs); young precursors are neuron re-
stricted while aged precursors are glial competent.
5–7 In
addition to poorly understood epigenetic changes that control
temporal competence to astrogliogenesis, extrinsic signals
are important determinants of astrocyte fate, including the
JAK-STAT pathway activated by cytokines such as LIF,
CNTF, and cardiotrophin 1 as well as BMP signalling acting
through the Smad transcription factor family.
8,9 Synergistic
interaction between these two signalling pathways raises the
possibility that dual activation of STAT and BMP signalling will
promote astrogliogenesis from human ES-derived neural
precursors.
10
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www.nature.com/cddWhile the underlying cause of individual neurodegenerative
diseases is unknown, multiple lines of evidence implicate
oxidative stress in disease pathogenesis.
11 The support of
neuronal antioxidant defences by astrocytes represents a
key neuroprotective role and its manipulation represents an
emerging therapeutic strategy for a range of acute and chro-
nic neurological disorders associated with oxidative stress.
12
One attractive target is the transcription factor nuclear factor-
erythroid 2-related factor 2 (Nrf2), a master regulator of
antioxidant defences and drug-metabolising enzymes. The
binding of Nrf2 to a cis-acting DNA promoter sequence called
the antioxidant response element (ARE), allows trans-activa-
tion of a group of genes that includes key components of the
glutathione antioxidant system.
13 Under normal conditions,
Nrf2 is bound in the cytoplasm by Kelch-like ECH-associated
protein 1 (Keap1) and targeted for proteasomal degrada-
tion.
14 However, the Keap1-dependent turnover of Nrf2 can
be inhibited by oxidative stress and a variety of small
molecules, leading to an accumulation of Nrf2 whereupon it
accumulates in the nucleus and activates ARE-driven genes.
Activation of Nrf2 by mild oxidative stress in astrocytes
contributes to neuroprotective ischaemic preconditioning,
15
although other mechanisms exist.
16 Furthermore, pharmaco-
logical activation of astrocytic Nrf2, or overexpression of Nrf2
in astrocytes, confers a neuroprotective response in rodent
models of Parkinson’s disease, and ALS.
17–19 The mech-
anism behind this non-cell-autonomous neuroprotection is
thought to be through the upregulation of astrocytic glu-
tathione biosynthesis and secretion, breakdown products
of which are used by the neurons to support their own
glutathione levels.
18 Noting inter-species functional differe-
nces, the relevance of these rodent-based astrocyte-mediated
neuroprotective effects to human experimental systems is
unknown.
20
Here, we describe a novel protocol for generating highly
enriched, functional astrocytes derived from human embryo-
nic stem cells (HESCs), using a combination of develop-
mental cues. By generating a separate population of neurons
derived from the same HESC line, we establish a human-
centred platform for assessing the neuroprotective properties
of compounds when administered either directly to neurons,
or in triggering a non-cell-autonomous neuroprotective res-
ponse in astrocytes. As proof-of-concept, we demonstrate a
key capacity for human astrocytes to mediate neuroprotective
responses, including those triggered by a small molecule
activator of Nrf2 that can only act in this non-cell-autonomous
manner.
Results
Generation of enriched and functional astrocytes from
human ES cells. In order to establish a platform to study
astrocyte–neuronal interactions, we ﬁrst generated a stable
human neural precursor cell (hNPC) population. Using establi-
shed protocols, HESC neural aggregates were ﬁrst derived.
21
At day 8, neural aggregates were mechanically dissociated
and plated as an adherent monolayer in deﬁned conditions
on gelatin, selecting for neural rosette-like structures at each
passage.
22 By day 30, a near homogeneous population of
hNPCs were obtained that were both nestin and 3CB2
positive (93.9±1.0% and 82.7±2.1%, respectively; Figures
1a and b) and had a bipolar morphology consistent with a
radial glial identity.
In order to generate astroglia, hNPCs were further
propagated until day 55 when they expressed, along with
nestin,andkeyreceptorsanddownstreamsignallingeffectors
for astrogliogenesis. These included BMP and LIF receptors
and, SMAD1 and STAT3, by RT-PCR (Figure 1c). Having
previously shown that BMP4 promotes astrogliogenesis,
5 we
sought to reﬁne this process in order to obtain more enriched
astroglial populations for further enrichment. We system-
atically tested the efﬁcacy of BMP4 alone and in combination
with LIF and BMP2, which have been shown previously to
promote astroglial commitment.
9,10 Astroglial speciﬁcation
was screened by measuring differential gene expression of
brain lipid binding protein (BLBP), a neural precursor marker,
and glutamine synthetase (GS), an astrocyte-expressed
enzyme required for production of glutathione and glutamate
recycling in neurotransmission. Gene expression analysis
revealeddownregulation ofBLBP andupregulationofGSwith
all treatment groups relative to control (Po0.05). The com-
bination of BMP4 and LIF resulted in the greatest change in
gene expression (Figure 1d). Quantitative immunohistochem-
istry was next undertaken with astrocyte differentiation deter-
mined by downregulation of nestin and concomitant upregula-
tionofGFAPstaining,alongwithachangeinmorphologyfrom
bipolar to stellate. Although all treatment groups increased
the numbers of cells with GFAP staining, the combination
of BMP4 and LIF resulted in the greatest upregulation
(88.4±2.0% versus control 35.8±3.6%; Figures 1e–h).
Prolonged exposure (12 days) to BMP4 and LIF increased
GFAP-positive staining to 95.7±3.1%. Furthermore, GFAP-
positive astrocytes derived by BMP4/LIF co-treatment also
stained positive for other markers of astrocyte differentiation;
aquaporin 4 (79.4±1.0%) (Figure 1i), S100b (90.1±2.0%)
(Figure 1j), and EAAT1 (89.5±3.2%) (Figure 1k). A deﬁning
physiological role of astrocytes is glutamate uptake mediated
by Na
þ-dependent channels that include members of the
excitatory amino-acid transporter family EAAT1 and EAAT2.
23
Radiolabelled glutamate uptake assays revealed negligible
hNPC uptake in contrast to robust Na
þ-dependent glutamate
uptake by BMP4/LIF-derived astrocytes consistent with
astrocyte function (Figure 1l). Combined BMP4/LIF treatment
was therefore used for subsequent functional and neuro-
protection experiments.
Human astrocytes attenuate oxidative neuronal injury.
Having established functional hNPC-derived astrocytes, we
next generated an enriched population of neurons from
HESCs in order to examine human astrocyte–neuronal inter-
action in the context of oxidative stress. Neural stem cells
were generated from H9 HESCs as described by Koch
et al.
22; following differentiation for 10 days 95.5±1.4% were
TuJ1 positive upon immunostaining (Figure 2a). Studies
predominantly based in rodent systems have shown that
astrocytes can release soluble factors that support the growth,
development, and survival of neurons, and so astrocyte-
conditioned medium (ACM) can be neuroprotective.
24 We
therefore sought to determine whether medium conditioned
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Cell Death and DifferentiationFigure 1 Derivationof astrocytes from HESCs.hNPC markers were quantiﬁedby immunohistochemistryfor (a) nestinand (b) 3CB2-positive staining(scale bar, 100mm)
andanalysedfor(c)thepresenceofBMPandLIFsignallingmediatorsbyRT-PCR.hNPCsweretreatedwithBMP2,BMP4,andLIFincombinationand(d)mRNAexpression
ofBLBPandGS analysedbyquantitativereal-timePCR, normalisedto GAPDH.*Po0.05ANOVA,Newman–Keulspost-test(n¼3).Astrocyteyieldwas conﬁrmedby(e–h)
quantiﬁcation of GFAP-positive immunostaining (scale bar, 100mm), and (i–k) the presence of astrocyte markers AQP4, S100b and EAAT1 was examined to conﬁrm
astrocyte identity (scale bar, 50mm). *Po0.05 ANOVA, Newman–Keuls post-test (n¼3). (l) Astrocyte function was conﬁrmed by examining sodium-dependent glutamate
uptake. *Po0.05 paired t-test (n¼3)
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Cell Death and Differentiationby HESC-derived astrocytes could exert a neuroprotec-
tive effect on HESC-derived neurons, using H2O2 to model
an oxidative insult (Figures 2b and c). Cell death in response
to H2O2 treatment was quantiﬁed with the CellTiter-glo
assay and conﬁrmed by quantitative immunohistochemistry
determining activated caspase-3/TuJ1 positive co-staining
(Figures 2d–f). Addition of ACM resulted in a signiﬁcant
neuroprotective effect against H2O2-induced injury, compa-
red with unconditioned medium (31.0±1.8% loss of viability
compared with control: 41.4±1.4% loss of viability; Figure 2c,
Po0.05). Immunoﬂuorescent analysis of caspase-3 activa-
tion revealed similar results: treatment of neurons with 50mM
H2O2 caused an increase of active caspase-3-positive
neurons from 1.5±0.7% to 43.6±5.0%; however, the pre-
sence of ACM reduced the level of H2O2-induced caspase-3
activation to 30.2±2.5% (Figures 2d–f). Thus, human
astrocytes are able to protect neurons against oxidative
insults through the release of soluble factors.
CDDO
TFEA treatment reveals glutathione-dependent
and glutathione-independent mechanisms for astrocyte-
mediated neuroprotection. Nrf2 activation in rodent
astrocytes can confer increased antioxidant capacity on
neurons by mechanisms that include enhanced glutathione
biosynthesis and secretion.
15,18,19 There is also growing
evidence for Nrf2-activating synthetic triterpenoids as poten-
tial therapeutic agents in experimental models of neuro-
degenerative diseases associated with oxidative stress.
25 To
test their relevance to human systems, we examined whether
the triterpenoid CDDO
TFEA26 could induce Nrf2 target gene
expression in human astrocytes and whether this leads to an
enhanced neuroprotective response.
We ﬁrst studied the expression of two Nrf2 target genes,
NFE2L2 (encoding Nrf2 itself) and GCLC (the glutamate-
cysteine ligase catalytic subunit). The GCLC gene encodes
the catalytic subunit of GCL, which performs the rate-limiting
step in glutathione biosynthesis. Compared with neurons,
Figure 2 ACM protects neurons from peroxidative injury. Highly enriched HESC-derived neurons demonstrated (a) 495% TuJ1-positive immunostaining (scale bar,
100mm). (b) HESC-derived astrocyte cultures were used to condition minimal medium over 24h. (c) Enriched HESC-derived neuronal cultures were treated with H2O2
(50mM) for 6h in minimal medium and ACM, and neuronal viability quantiﬁed. (d–f) Representative TuJ1 and activated caspase-3 co-staining (scale bar, 50mm). *Po0.05
ANOVA, Newman–Keuls post-test (n¼3)
HESC-derived astrocytes mediate non-cell-autonomous neuroprotection
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Cell Death and DifferentiationastrocytesshowedfarhigherbasallevelsofbothNFE2L2and
GCLC, indicative of a higher basal Nrf2 activity (Figure 3a).
Moreover, these levels were further increased by treatment of
astrocytes with CDDO
TFEA (Figure 3a). Consistent with an
upregulation in GCLC expression, cell-free extracts taken
from CDDO
TFEA-treated astrocytes exhibited elevated levels
ofGCLenzymeactivity(24h,46.8±18%greaterthancontrol)
(Figure 3b). To determine whether this in turn translated to
increased glutathione levels in astrocytes, we assessed
intracellular glutathione content using an assay based on
monochlorobimane (MCB). MCB is non-ﬂuorescent in its
native state and becomes ﬂuorescent upon conjugation to
glutathione in the cell.
27 CDDO
TFEA treatment of astrocytes
resulted in a substantial increase in glutathione levels (6h,
34.7±13.8% greater than control, Po0.05; 24h, 54.4±
17.7% greater than control, Po0.05; Figure 3c) that was
completely blocked by co-treatment with the GCL inhibitor
buthionine sulfoximine (BSO) (CDDO
TFEA/BSO:  37.3±
14.5% at 6h,  65.8±6.3% at 24h; BSO:  16.1±8.4% at
6h,  63.0±3.8% at 24h; Figure 3c). Thus, CDDO
TFEA
treatment of human astrocytes upregulates Nrf2 target gene
expression, GCL enzyme activity, and glutathione production,
raising the possibility that this inﬂuences their neuroprotective
capacity.
Before investigating the capacity of CDDO
TFEA to boost
astrocyte-mediated neuroprotection in our human system, we
ﬁrst sought to establish its dependence on Nrf2 using cultures
derived from wild-type and Nrf2-deﬁcient mice. We ﬁrst
established that CDDO
TFEA-mediated neuroprotection re-
quired the presence of astrocytes (Figure 4a). CDDO
TFEA
treatment protected neurons against H2O2-induced death in
mixedNrf2
þ/þ corticalcultures(90%NeuN-positiveneurons,
10% GFAP-positive astrocytes;
15,25 however, no protection
was observed in astrocyte-free Nrf2
þ/þ neuronal cultures
(Figure 4a). We then investigated the Nrf2 dependence of
CDDO
TFEA-induced neuroprotection (Figure 4b). We found
that CDDO
TFEA-induced neuroprotection of mixed cultures
was dramatically diminished in Nrf2
 /  mixed cultures,
compared with those from Nrf2
þ/þ mice. These data indicate
thatCDDO
TFEA-mediated neuroprotectionis indeed mediated
through its effects on the Nrf2 pathway (Figure 4b).
To investigate whether CDDO
TFEA treatment of human
astrocytes can promote protection of human neurons, astro-
cytes were treated with or without CDDO
TFEA for 6h, in the
presence or absence of BSO, after which all drugs were
washed out and fresh medium added for the astrocytes to
condition for 24h (Figure 4c). Medium conditioned by
CDDO
TFEA-treated astrocytes was signiﬁcantly more neuro-
protective against oxidative injury than medium conditioned
by untreated astrocytes as determined by viability assay and
active caspase-3 immunohistochemistry (Figures 4d–g). The
enhanced protective response induced by CDDO
TFEA was
blockedifGCLactivitywasinhibitedbyco-treatmentwithBSO
(Figures 4d and g), implicating enhanced astrocytic GCL
activity and glutathione production as the mechanism under-
lying protection conferred by CDDO
TFEA treatment in contrast
to a glutathione-independent protective effect mediated by
basal untreated astrocytes (Figure 4d). We next examined
whether CDDO
TFEA treatment of neurons alone was also pro-
tective against oxidative injury. Unlike astrocytes, CDDO
TFEA
treatmentofneuronsfailedtoinduceNFE2L2orGCLCmRNA
expression (1.25±0.2, 1.23±0.1 fold change) (Figure 4h),
and importantly conferred no signiﬁcant protective effect
against H2O2-induced oxidative injury, at a range of concen-
trations (Figure 4i). These ﬁndings reveal that CDDO
TFEA can
only exert its human neuroprotective effects non-cell-auton-
omously via Nrf2 activation and glutathione production in
astrocytes. Thus, basal and CDDO
TFEA-induced astrocyte-
mediated neuroprotection against oxidative injury involves
distinct glutathione-dependent and glutathione-independent
mechanisms.
Discussion
The role of the glial environment in modulating health, injury,
and protection of neurons is becoming increasingly well
recognised.
1,28 In order to further understand the relevance
of glial signalling to human neuronal injury, there is a need to
ﬁrst establish appropriate human systems of glial–neuronal
interaction. This study highlights the utility of HESCs for
in-vitro human glial–neuronal modelling and demonstrates
generation of highly enriched functional human astrocytes
that promote survival of neurons following oxidative injury. In
addition, we ﬁnd that human astrocytic neuroprotective res-
ponses involve multiple mechanisms and can be manipulated
by small molecules.
Previous studies have focussed predominantly on neuronal
differentiation of HESCs with some modelling of isolated
neuronal injury.
1,2 In contrast, the study of functional HESC-
derived astrocytes is limited with negligible investigation of
Figure 3 Astrocytes upregulate NRF2 pathway with CDDO
TFEA treatment. (a) mRNA expression of NFE2L2 and GCLC were examined by quantitative real-time PCR,
normalised to GAPDH. Cell types examined included enriched human neuron and astrocyte cultures, and human astrocyte cultures treated with CDDO
TFEA (250nM) for 6h.
*Po0.05, **Po0.01 paired t-test (n¼3). (b) GCL enzyme activity was examined in enriched human astrocyte cultures treated with CDDO
TFEA (250nM) for 6h. *Po0.05
paired t-test (n¼3). (c) Enriched human astrocytes were treated with CDDO
TFEA (250nM), BSO (200mM), and CDDO
TFEA þ BSO for 6h and 24h, and intracellular GSH
quantiﬁed by the MCB assay. *Po0.05 ANOVA, Newman–Keuls post-test (n¼3)
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Cell Death and Differentiationhuman glial–neuronal interaction. Astrocytic differentiation is
determined temporally by intrinsic mechanisms
5 and exogen-
ousfactors, including BMP4and LIF;
9LIF and other members
of the IL-6 cytokine family have been shown to synergi-
stically drive astroglial differentiation in conjunction with
BMPs, STAT3, and SMAD1 converging upon CBP/p300,
Figure 4 CDDO
TFEA drug treatment is neuroprotective by a GSH-dependent, astrocyte-mediated mechanism. (a) CDDO
TFEA-induced neuroprotection requires the
presence of astrocytes. Mixed mouse cortical cultures (90% NeuNþ neurons, 10% GFAPþ astrocytes) or astrocyte-free mouse neuronal cultures (498% NeuNþ,
o0.2% GFAPþ) were treated with CDDO
TFEA (100nM) for 24h, before treatment with H2O2 (100mM) for a further 24h, after which cultures were ﬁxed and levels of cell
deathassessed.*Po0.05pairedt-test(n¼4).(b)CDDO
TFEA-inducedneuroprotectionisNrf2-dependent.CDDO
TFEA-inducedneuroprotectioninmixedNrf2
þ/þ orNrf2
 / 
mouse cortical cultures was studied using the same protocols as (a). *Po0.05 paired t-test (n¼4). (c) Enriched human astrocyte cultures were treated with CDDO
TFEA
(250nM)±BSO(200mM)for6h,thedrugwashedout,andfreshminimalmediumreplacedforconditioningover24h.ACMwasderivedaspreviouslyandsupplementedwith
H2O2.(d)Humanneuronalviabilitywas assessedupontreatmentwith H2O2(50mM) for 6h, inACM derivedfromuntreatedandCDDO
TFEA-treated enrichedastrocytes.BSO
co-treatment was used to block GCL activity, demonstrating GCL-dependent and -independent neuroprotective effects of ACM. (e–g) Representative TuJ1 and activated
caspase-3 co-staining (scale bar, 50mm). *Po0.05 ANOVA, Newman–Keuls post-test (n¼3). (h) Human neuronal expression of NFE2L2 and GCLC mRNA with 6h
CDDO
TFEA (250nM) treatment were examined by quantitative real-time PCR. (i) The effect of treatment with CDDO
TFEA (250nM) for 24h on human neuronal viability was
determined over a range of H2O2 concentrations (0–200mM, 6h). *Po0.05 paired t-test (n¼3)
HESC-derived astrocytes mediate non-cell-autonomous neuroprotection
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Cell Death and Differentiationrespectively.
10 We extend our previous observations
5 and
demonstrate scaleable generation of highly enriched astro-
cytes from HESCs through BMP4 and LIF application to late
neural precursors. Accurate glial–neuronal disease modelling
requires prior demonstration of function. While this study has
been in preparation, Krencik et al.
4 described the use of LIF/
CNTF-mediated astrocyte differentiation from HESC-derived
neural aggregates over 180 days, observing expression of
astrocyte-speciﬁc markers including GFAP/S100b and gluta-
mate uptake among other characterisation. We demonstrate
the use of co-operative BMP4/LIF signalling for similar levels
of astrocyte enrichment over a considerably shorter time
course. The astrocytes generated in this study express a
range of astrocyte markers; GFAP, AQP4, S100b, and
EAAT1 and also crucially demonstrate functional glutamate
uptake capacity.
There is growing evidence that astrocyte behaviour is
dynamic, potentially either beneﬁcial or detrimental for
neuronal survival. Accumulating in-vivo evidence highlights
a powerful neuroprotective effect of astrocytes.
29,30 We have
shown previously in a rodent transgenic model of human
P301S t-mediated neurodegeneration, that age-related loss
of neurons is reversed by astroglial transplantation.
29 Other
groups have shown similarly that astrocyte transplantation
in a rodent transgenic model of ALS expressing human
SOD1*G37R attenuated motor neuron loss and motor
decline.
30 Here, we demonstrate that HESC-derived astro-
cytes were able to protect neurons from oxidative injury by
soluble factors, through a mechanism independent of de novo
glutathione synthesis. Astrocytic supply of glutathione to
neurons has been implicated as a key mediator of neuronal
antioxidant defence;
18,31 baseline secretion of glutathione
remains a potential neuroprotective mechanism as the
duration of BSO treatment blocked de novo glutathione
synthesis and did not fully deplete astrocytes of intracellular
glutathione. Other soluble factor-mediated neuroprotective
mechanismsincludesecretionofneurotrophicfactorssuchas
GDNF and IGF-1.
29,32
Oxidative stress is particularly prevalent in neurodegen-
erative injury
11 and, as astrocytes are central to antioxidant
defence in the CNS,
33 modulation of astrocyte antioxidant
abilities has been considered a potential therapeutic target in
altering the clinical course of such disorders.
12,34 To this end,
activators of Nrf2 have received considerable atten-
tion.
12,15,17,19,35 Nrf2 modulation in astrocytes has a key role,
abating neurological injury and disease progression in mouse
models of ALS and Parkinson’s disease in a glutathione-
dependent manner.
17,19 We recently identiﬁed activation of
astrocytic Nrf2 as a contributor to endogenous neuroprotec-
tive responses in the context of ischaemic preconditioning.
15
The synthetic oleanane class of triterpenoids, which includes
CDDO analogues, presents a promising drug treatment in
multiple pathologies, due to their ability to modulate the
activity of Nrf2.
25 This study demonstrates that CDDO
TFEA is
capable of inducing strong neuroprotective responses in
human astrocytes via a glutathione-dependent mechanism.
Strikingly, human neurons derived from the same HESC line
were completely incapable of responding to CDDO
TFEA either
in terms of activation of Nrf2 target genes, or by eliciting a
neuroprotective effect. The reason behind this is unclear but
may be due to low levels of NFE2L2 mRNA (which encodes
Nrf2) in neurons (Figure 3a). However, it is consistent with the
observation from mixed rodent cultures that astrocytes
represent the major locus for Nrf2 activation, induced both
by small molecules and by oxidative stress.
15,18
Non-cell-autonomous neuroprotection, as shown in our
study, has widespread and fundamental implications for
human-based drug discovery and screening of novel neuro-
protective agents. Speciﬁcally, our ﬁndings suggest that
screens focussing solely on the direct effect of compounds
on isolated neurons will overlook potentially important
neuroprotective activities that act via astrocytes or other
non-neuronal cells. To conclude, these studies provide
important proof-of-concept that human stem cell derived
neural derivatives can be used effectively to model neuron–
astrocyte interactions and investigate their mechanism. In
the endeavour for clinically translatable interventions that
may abate the course of neurodegenerative disorders, a key
step in translation is the development of human in-vitro
platforms, for both disease modelling and drug screening.
HESC-based platforms overcome the issues of species-
speciﬁc drug responses and transcriptional changes, and
provide an important benchmark platform for studies using
patient-speciﬁc pluripotent lines and clinical translation.
Materials and Methods
ES culture and neuralisation. The HESC lines H9 and HUES9 (Harvard
University,Cambridge,MA,USA)wereculturedandpassagedregularlyonafeeder
layer of irradiated mouse embryonic ﬁbroblasts, and neuralised by established
protocols;
21 In order to derive adherent hNPCs, HESC-derived neurospheres were
dissociated and underwent selective propagation as an adherent monolayer on
gelatin, in chemicallydeﬁnedmedium
36 supplemented with 20ng/mlhumanFGF-2,
heparin 5mg/ml and 20ng/ml human EGF, with 2-day complete medium changes.
hNPCs were propagated for 2 months before astroglial differentiation. For astroglial
differentiation, coverslips were coated with Matrigel (BD Biosciences, Oxford, UK)
for 1h, diluted 1:30 in Dulbecco’s Modiﬁed Eagle’s Medium (DMEM). Conﬂuent
hNPCs were enzymatically dissociated with Accutase and plated in basic plating
medium(BPM)composedof4.5g/lglucoseDMEM(Invitrogen,Carlsbad,CA,USA)
supplemented with 2% B27 supplement minus antioxidants (Invitrogen) and 1%
penicillin-streptomycin.BPMwasmodiﬁedforeachplatingconditionwithBMP2and
BMP4 (R&D, Abingdon, UK) at ﬁnal concentrations of 10ng/ml, and LIF (Sigma,
St. Louis, MO, USA) at ﬁnal concentrations of 20ng/ml. Differentiating astrocytes
received full media changes with factor-supplemented BPM every 2 days. Neurons
underwent differentiation for 10 days in Neurobasal medium, supplemented with
2%B27supplementminusantioxidants,1%Glutamax(Gibco,Carlsbad,CA,USA),
1% non-essential amino acids, DAPT
37 and 10ng/ml BDNF.
Mouse mixed and astrocyte-free neuronal culture experiments.
Cortical mouse mixed cultures of neurons and astrocytes were prepared as
described
38 from E17.5 Nrf2
þ/þ and Nrf2
 /  mice with Neurobasal growth
medium supplemented with B27 (Invitrogen). Typically, these cultures are B90%
NeuN-positive neurons and 10% GFAP-positive astrocytes.
39 To obtain astrocyte-
free neuronal preparations (498% NeuNþ neurons and o0.2% GFAPþ
astrocytes
15), cultures were treated with antimitotic cytosine-arabinoside imme-
diately post-plating. Experiments were carried out on cultured neurons following a
period of 10 days during which cortical neurons develop a network of processes,
express functional NMDA-type and AMPA/kainate-type glutamate receptors, and
form synaptic contacts. CDDO
TFEA-induced neuroprotection against oxidative
insults was studied as described previously for
3H-1,2-dithiole-3-thione-induced
protection.
35 Before the start of experiments, cultures were placed in minimal
medium in the presence or absence of CDDO
TFEA (100nM), 16h before an
oxidativeinsultwasappliedintheformofH2O2(100mM,stabilisedsolution;Sigma).
Cultures were ﬁxed 24h later and analysed after DAPI staining; cell death
was quantiﬁedby counting(blind)thenumberofapoptoticnucleiasa percentageof
the total. Approximately 1500 cells were counted per treatment, across four
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Cell Death and Differentiationindependent experiments. Morphologically, H2O2-treated neurons show typical
signs of apoptotic-like cell death (shrunken cell body and large round
chromatin clumps).
Gene expression analysis. Total RNA was isolated via the Absolutely RNA
miniprep kit, cDNA synthesis performed via the AfﬁnityScript cDNA (Stratagene,
Stockport, UK) synthesis kit using oligo-dT and random hexamerprimers, and qRT-
PCR performed using Brilliant SYBR Green master mix (Stratagene), following the
manufacturer’s instructions. RT-PCRs were run over 28 cycles, and PCR products
were separated on a 1.6% agarose in TBE gel, with GelRed for DNA visualisation.
Primer sequences are listed in Supplementary Table S1.
Immunohistochemistry. Cells plated on glass coverslipswereﬁxed with 4%
paraformaldehyde for 20min at room temperature and washed three times with
PBS.Sampleswerenextblockedfor1hatroomtemperaturewith0.2%Triton/PBS/
5% goat serum and then incubated overnight with primary antibody in 0.2% Triton/
PBS/2% goat serum at 41C. After three washes in PBS, secondary antibody
(Alexa Fluor, 1:1000) in PBS/DAPI (1:4000) was next applied for 1h at room
temperature. Primary antibodies used included Nestin (1:300; Chemicon, Bedford,
MA,USA),3CB2(1:5;DevelopmentalStudiesHybridomaBank(DSHB),IowaCity,
IA, USA), GFAP (1:300; Dako; 1:500; Abcam, Cambridge, UK), S100b (1:300;
Dako, Ely, UK), AQP4 (1:50; Santa Cruz, Santa Cruz, CA, USA), EAAT1 (1:200;
Novus Biologicals, Cambridge, UK), TuJ1 (1:500; Sigma-Aldrich) and activated
caspase-3 (1:50; Chemicon).
Glutathione determination. Intracellular glutathionecontent was measured
by the MCB (Sigma) assay. MCB is non-ﬂuorescent in its native state and
ﬂuorescent upon conjugation with thiol-containing molecules including glutathione.
While the MCB assay does not exclude other thiol-containing molecules in addition
to glutathione,quantiﬁcationof ﬂuorescencehas been used successfully to quantify
GSH content.
27 Cells were incubated in minimal mediumcontaining 50mM MCB for
45min. Medium was removed and the cells were lysed; cell membranes were
pelleted by centrifugation at (15000r.p.m., 5min), and the ﬂuorescence of the
supernatant read by plate reader (FLUOstar OPTIMA, BMG Labtech, Aylesbury,
UK) (excitation 405nm/emission 520nm). Fluorescence values obtained were
adjustedforbackgroundsignalandnormalisedtoproteinconcentration,determined
by BCA absorbance assay using bovine serum albumin standards.
Glutamate uptake. Plated astrocytes were washed twice in Tissue Buffer
(5mM Tris, 320mM sucrose, pH 7.4) and then exposed to 10mM
3H-glutamate in
either Na
þ-containing Krebs buffer (120mM NaCl, 25mM NaHCO3, 5mM KCl,
2mM CaCl2, 1mM KH2PO4, 1mM MgSO4, 10% glucose) or Na
þ-free Krebs
(120mM choline-Cl and 25mM Tris-HCl, pH 7.4 substituted for NaCl and NaHCO3,
respectively)for10minat371C.Uptakewasstoppedbyplacingtheastrocytesback
on ice and washing them twice with Wash Buffer (5mM Tris/160mM NaCl pH 7.4).
Cells were lysed with 0.1M NaOH and radioactivity measured using a scintillation
counter. Na
þ-dependent uptake was determined by subtracting Na
þ-free counts
from total counts in the presence of Na
þ.
GCL enzyme kinetic assay. Reaction buffer and lysis buffer were prepared
as described previously.
40 ATP and cysteine hydrochloride were prepared fresh.
Cells were lysed in 350ml of lysis buffer, and cell debris pelleted (13000r.p.m.,
10min).Inall,50mlofcelllysatewasplacedat371Cforeachofﬁvetimepoints,and
50ml of reaction buffer and 40mM ATP added. After 5min equilibration, 50ml
20mM cysteine hydrochloride was added, for 30, 20, 10, and 5min, and at time 0.
The reaction was terminated by the addition of 50ml metaphosphoric acid, and
placement on ice. Precipitated proteins were pelleted (2500r.p.m., 5min), and
glutamyl-cysteine quantiﬁed by NDA ﬂuorescence. In all, 20ml of reaction mixture
was combined with 180ml of NDA reaction mixture, comprising 140ml Trizma-base
50mM, 20ml 1M NaOH, 20ml NDA 10mM, and ﬂuorescence determined by plate
reader (excitation 485nm/emission 520nm).
Conditioned medium generation. Astrocytes were treated with minimal
medium, consisting of Salt–Glucose–Glycine
39 supplemented with 10% MEM
(Invitrogen), in the presence and absence of drugs for 6h, after which the drugs
were washed out and fresh minimal medium replaced. Drugs included 1[2-Cyano-
3,12-dioxool-eana-1,9(11)-dien-28-oyl] triﬂuoroethylamide (CDDO
TFEA; 250nM),
BSO (200mM), and bischloronitrosurea (BCNU; 50mM). After 24h, ACM was
removed, cell debris pelleted (41C, 3400r.p.m. for 10min), and half-supplemented
with fresh minimal medium before the addition of H2O2 and neuronal viability
determined.
Neuronal injury and cell viabilityassays. Neurons were preconditioned
in minimal medium for 12h, before addition of control or astrocyte-conditioned
minimalmediumsupplementedwithH2O2.Afterperoxidativechallenge,cellviability
was quantiﬁed using CellTiter-Glo Luminescent Cell Viability Assay (Promega,
Madison, WI, USA), following the manufacturer’s instructions. In brief, assay
reagents were reconstituted according to instructions, and an equal volume added
to cell medium. After 10min, cell lysate was removed and luminescence quantiﬁed
by plate reader.
Data analysis. All experiments were performed with at least three biological
repeats; within each, three technical repeats were generated. Experiments were
repeated across two independent HESC lines. qPCR data were normalised to
GAPDH. For quantitative IHC, ﬁve random views were taken per coverslip, and cell
counts were performed manually, assessing staining speciﬁcity and morphology.
Dataarepresentedasmean±standarderrorofthemean;statisticalanalyseswere
performedinMicrosoftExcelandGraphPadPrism5(GraphPadSoftware,Inc.,San
Diego, CA, USA) by univariate and two-way ANOVA with Newman–Keuls post-test
and the Students’ t-test. A P-value of 0.05 was considered statistically signiﬁcant.
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